Duchenne Breakthrough Hopes Rise With More Data From Sarepta Gene Therapy

Phase II Data Bodes Well For Pivotal EMBARK Trial

 
• By Andrew McConaghie
  
Sarepta building
Sarepta expect to complete dosing in their Phase III EMBARK study later this year, with a first readout then due in mid-2023 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip